Equities research analysts forecast that Colgate-Palmolive (NYSE:CL) will announce sales of $4.05 billion for the current quarter, according to Zacks. Five analysts have provided estimates for Colgate-Palmolive’s earnings, with the highest sales estimate coming in at $4.08 billion and the lowest estimate coming in at $4.02 billion. Colgate-Palmolive posted sales of $3.88 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 4.4%. The company is expected to issue its next earnings report on Friday, April 24th.

On average, analysts expect that Colgate-Palmolive will report full-year sales of $16.41 billion for the current fiscal year, with estimates ranging from $16.35 billion to $16.53 billion. For the next fiscal year, analysts forecast that the company will post sales of $16.96 billion, with estimates ranging from $16.87 billion to $17.11 billion. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Colgate-Palmolive.

Colgate-Palmolive (NYSE:CL) last announced its quarterly earnings results on Friday, January 31st. The company reported $0.73 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.73. Colgate-Palmolive had a return on equity of 1,906.25% and a net margin of 15.08%. The company had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.93 billion. During the same period in the prior year, the company earned $0.74 earnings per share. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year.

Several research analysts have recently weighed in on CL shares. Morgan Stanley upped their price objective on Colgate-Palmolive from $71.00 to $76.00 and gave the stock an “equal weight” rating in a research report on Monday, February 3rd. Deutsche Bank upped their price objective on Colgate-Palmolive from $72.00 to $73.00 and gave the stock a “hold” rating in a research report on Thursday, December 12th. TheStreet raised Colgate-Palmolive from a “c+” rating to a “b” rating in a research report on Friday, January 31st. Royal Bank of Canada raised Colgate-Palmolive from a “sector perform” rating to an “outperform” rating and upped their price objective for the stock from $69.00 to $91.00 in a research report on Monday, February 3rd. Finally, Bank of America cut Colgate-Palmolive from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $77.00 to $74.00 in a research report on Thursday, December 19th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $75.00.

Shares of Colgate-Palmolive stock traded down $1.85 during trading hours on Monday, hitting $74.42. The company’s stock had a trading volume of 5,373,653 shares, compared to its average volume of 4,260,187. Colgate-Palmolive has a 12 month low of $64.75 and a 12 month high of $77.41. The stock has a 50 day moving average of $72.83 and a 200 day moving average of $70.52. The company has a market capitalization of $65.37 billion, a PE ratio of 27.06, a price-to-earnings-growth ratio of 5.56 and a beta of 0.70. The company has a debt-to-equity ratio of 43.94, a current ratio of 0.37 and a quick ratio of 0.24.

The business also recently disclosed a quarterly dividend, which was paid on Friday, February 14th. Shareholders of record on Thursday, January 23rd were paid a dividend of $0.43 per share. The ex-dividend date was Wednesday, January 22nd. This represents a $1.72 dividend on an annualized basis and a yield of 2.31%. Colgate-Palmolive’s dividend payout ratio (DPR) is presently 60.78%.

In other Colgate-Palmolive news, SVP John J. Huston sold 35,213 shares of the firm’s stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $76.30, for a total value of $2,686,751.90. Following the sale, the senior vice president now owns 84,260 shares of the company’s stock, valued at approximately $6,429,038. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CMO John W. Kooyman sold 21,294 shares of the firm’s stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $76.33, for a total value of $1,625,371.02. Following the completion of the sale, the chief marketing officer now directly owns 17,676 shares in the company, valued at approximately $1,349,209.08. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 220,090 shares of company stock worth $16,418,383. Corporate insiders own 1.14% of the company’s stock.

Several hedge funds have recently modified their holdings of CL. Quest Capital Management Inc. ADV acquired a new stake in shares of Colgate-Palmolive during the 3rd quarter valued at $31,000. Horan Capital Advisors LLC. acquired a new stake in shares of Colgate-Palmolive during the 3rd quarter valued at $32,000. KCS Wealth Advisory acquired a new stake in shares of Colgate-Palmolive during the 3rd quarter valued at $34,000. Peddock Capital Advisors LLC acquired a new stake in shares of Colgate-Palmolive during the 4th quarter valued at $34,000. Finally, Pacifica Partners Inc. acquired a new position in Colgate-Palmolive during the 4th quarter worth about $36,000. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

About Colgate-Palmolive

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. It offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; and personal care products, such as liquid hand soaps, bar soaps, shower gels, deodorants and antiperspirants, skin care products, and shampoos and conditioners.

See Also: Outstanding Shares, Buying and Selling Stocks

Get a free copy of the Zacks research report on Colgate-Palmolive (CL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.